【レポートの概要（一部）】
1. Executive Summary
1.1 Overview
1.2 Review of the Vaccine Manufacturing Technology and Services Market
1.3 Aims, Scope and Format of Report
1.4 Research and Analysis Methods
2. Introduction to the Vaccine Market
2.1 What Are Vaccines?
2.2 The History of the Vaccine Market
2.3 The Vaccine Contract Manufacturing Market
2.3.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
2.3.2 Reasons to Outsource
2.3.3 Benefits of Outsourcing
2.3.4 The Challenges in Outsourcing Vaccine Manufacturing
2.3.5 Why Should Companies Outsource Vaccine Manufacturing?
2.3.6 Strategic Outsourcing vs. Tactical Outsourcing
2.3.7 Virtual Companies
2.3.8 Contract Manufacturing Organisations (CMOs)
2.3.9 Manufacturing Services Offered by CMOs
2.3.10 Vaccine Manufacturing Activities Typically Outsourced
3. Vaccine Manufacturing Technologies 2014
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift Towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago’s Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax’s Sf9/BV Technology
3.2.6.2 Protein Sciences Corporation (PSC): First Egg-Free Influenza Vaccine
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Leading Pre-Filled Vaccine Products 2014
3.5.3 Drivers and Restraints for Pre-filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges with Some Flu Vaccine
3.5.4.3 Novartis’ Agriflu and Fluad Ban is Lifted
3.5.4.4 Baxter Flu Vaccine and Side Effects
3.5.4.5 Reported Shelf Life Issues of Some H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.7 Cell Media Can Improve Virus Yield
4. The Vaccine Market 2014-2024
4.1 The Global Vaccine Market, 2014-2024
4.2 The Global Vaccine Market By Submarket, 2012 and 2013
4.3 The Global Vaccine Market by Submarket, 2014-2024
4.4 The Paediatric Vaccine Submarket Forecast, 2014-2024
4.4.1 Growth of Paediatrics Vaccines is Driven by Prevnar’s Blockbuster Success
4.4.2 Paediatric Vaccines: The Biggest Segment, but the Least Dynamic
4.4.3 Paediatric Vaccine Pipeline
4.5 The Adult Prophylactic Vaccine Submarket Forecast, 2014-2024
4.5.1 Adult Vaccination: Low Uptake
4.5.2 Gardasil Represented Nearly a Fifth of Segment Revenues in 2012
4.5.3 Adult Prophylactic Vaccines: Extensive Pipeline, but Still Needs to Become More Widely Established
4.5.4 Adult Prophylactic Vaccine Pipeline
4.6 The Influenza Vaccine Submarket, 2014-2024
4.6.1 Influenza: Growth is Driven by Seasonal Epidemics and Global Pandemics
4.6.2 Significant Scope for Enlarging the Patient Population
4.6.3 Influenza Market: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed
4.6.4 Influenza Product Pipeline
4.7 The Therapeutic Vaccine Submarket, 2014-2024
4.7.1 Therapeutic Vaccines: the Holy Grail of Personalised Vaccines
4.7.2 Therapeutic Vaccines: On the Cusp of an Explosion or Another Vaccine Hype?
4.7.2.1 Underperformance: Provenge is the First and Only FDA Approved Cancer Vaccine
4.7.2.3 Biovac ID Completes Phase III for Cancer Vaccine
4.7.3 Anti-Allergy Vaccines Make Up Bulk of Segment in 2013
4.7.3.1 Canada Gives Merck & Co. its First Approval for Grass Allergy Vaccine Tablet
4.7.3.2 Therapeutic Vaccine Product Pipeline
5. The Global Vaccine Contract Manufacturing Market 2014-2024
5.1 Global Vaccine Contract Manufacturing: A Tiny Fraction of The Total Vaccine Market
5.2 The Vaccine Contract Manufacturing Market Forecast: High Growth Rates from 2014-2024
5.2.1 Trends in the Vaccine Contract Manufacturing Forecast
5.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.3.1 The Leading National Markets for Vaccine Contract Manufacturing: Largely Dictated by the Local Vaccine Market
5.3.2 The Leading National Markets for Vaccine Contract Manufacturing, 2012 and 2013
5.3.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.4 The US Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5 The Japanese Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5.1 CMO’s in Japan
5.6 The EU5 Vaccine Contract Manufacturing Market, 2012 and 2013
5.6.1 The EU5 Vaccine Contract Manufacturing Market, 2014-2024
5.6.2 The French Vaccine Contract Manufacturing Market, 2014-2024
5.6.3 The German Vaccine Contract Manufacturing Market, 2014-2024
5.6.4 The Italian Vaccine Contract Manufacturing Market, 2014-2024
5.6.5 The Spanish Vaccine Contract Manufacturing Market, 2014-2024
5.6.6 The UK Vaccine Contract Manufacturing Market, 2014-2024
5.7 The Brazilian Vaccine Contract Manufacturing Market, 2014-2024
5.8 The Russian Vaccine Contract Manufacturing Market, 2014-2024
5.9 The Indian Vaccine Contract Manufacturing Market, 2014-2024
5.10 The Chinese Vaccine Contract Manufacturing Market, 2014-2024
5.10.1 Vaccine Manufacturing: Questioning China’s Regulatory Standards
6. The Leading Vaccine Contract Manufacturing Companies 2014-2024
6.1 The Vaccine Contract Manufacturing Market has Room for Consolidation
6.2 Baxter BioPharma Solutions
6.2.1 Business Capabilities
6.3 Boehringer Ingelheim
6.3.1 Recent Financial Performance
6.3.2 Boehringer Ingelheim’s Ben Venue Closure
6.3.3 Manufacturing Deals 2011-2014
6.3.4 Boehringer Ingelheim Implements Fully Disposable Biopharmaceutical Manufacturing
6.3.5 Boehringer Ingelheim Expands Biopharmaceuticals in China
6.3.6 Outlook
6.4 Catalent
6.4.1 Recent Financial Performance, 2008-2012
6.4.2 Recent Financial Performance by Segment, 2008-2012
6.4.3 Catalent Injectable Vaccines
6.4.4 Catalent Adjusts its Services
6.4.5 Future Strategies for Growth
6.4.6 Regional Market Expansion
6.5 Charles River Laboratories
6.5.1 Recent Financial Performance, 2008-2012
6.5.2 Recent Financial Performance, 3Q 2013
6.5.3 Recent Financial Performance by Segment
6.5.4 Vaccine Manufacturing Services
6.5.4.1 Vaccine Manufacturing Expansion
6.5.5 Future Outlook and Early Stage Restructuring
6.5.6 Partnerships
6.5.6.1 Partnership with AstraZeneca
6.5.6.2 Partnership with Batavia
6.6 IDT Biologika GmbH
6.6.1 Facility Expansion
6.6.2 Acquisitions and Partnerships
6.6.2.1 Acquisition of Riemser Pharma GmbH
6.6.2.2 Partnership with ImVisioN Therapeutics
6.7 Lonza
6.7.1 Recent Financial Performance, 2010-2012
6.7.1.1 Recent Financial Performance by Segment,2012
6.7.2 Manufacturing Division Restructuring
6.8 Meridian Life Science
6.8.1 Recent Financial Performance, 2008-2013
6.8.1.1 Recent Financial Performance by Segment, 2008-2013
6.8.1.2 Recent Financial Performance by Region, 2012-2013
6.9 Sigma-Aldrich
6.9.1 Revenue and Recent Performance Analysis, 2010-2013
6.9.1.1 Recent Financial Performance by Segment, 2010-2012
6.9.1.2 Segment restructuring, 2013
6.9.2 Strategy for Business Growth by Asian Expansion
6.9.3 Acquisition of BioReliance
6.9.4 Partnership with CatScl
6.10 SynCo Bio Partners
6.10.1 Recent Developments
6.10.1.1 Expansion of Facilities
6.10.1.2 FDA Approval of Partner Application
6.11 OSO BioPharmaceuticals Manufacturing
6.11.1 Facilities and Capabilities
6.11.2 New Developments
6.11.2.1 Acquisition of Catalent’s Sterile Injectables Manufacturing Business
6.11.2.2 Facility Investment
6.12 Leading Vaccine Contract Manufacturing Organisations
7. SWOT Analysis of the Vaccine Contract Manufacturing Market 2014-2024
7.1 Vaccine Contract Manufacturing Industry Trends
7.2 Strengths
7.2.1 Many Companies Cannot Afford In-house Capabilities
7.2.2 Outsourcing Improves Time to Market
7.2.3 Manufacturers get Access to Specialised Technologies
7.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
7.3 Weaknesses
7.3.1 Mass Vaccine Manufacturing is Kept In-house
7.3.2 A Highly Fragmented Vaccine Contract Manufacturing Market
7.3.3 An Unpredictable Supply and Demand Business Model
7.3.4 Lack of Differentiation in the CMO Space
7.4 Opportunities
7.4.1 Many Vaccines in the Product Pipeline
7.4.2 Therapeutic Vaccine Market could Explode
7.4.3 Emerging Market’s Growing Demand for Vaccines
7.4.3.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
7.5 Threats
7.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capitalist Funding
7.5.2 The Public are Slow to Accept Novel Technologies
7.5.3 Perception of Risk by the Original Vaccine Manufacturers
8. Expert Opinion
8.1 Interview with Dr. Eluemuno Blyden, CEO and Founder, AfriVax
8.1.1 The Egg-based Vaccine Manufacturing Myth
8.1.2 AfriVax’s New Vaccine Manufacturing Technology
8.1.3 Emerging Markets Pathing their Own Vaccine Path
8.2 Interview with Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
8.2.1 Growth of the Vaccine Contract Manufacturing Market
8.2.2 The Therapeutic Vaccine Market
8.2.3 The Use of Emerging Market Facilities
8.2.4 The Vaccine Contract Manufacturing Business Model
8.3 Interview with Dr Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
8.3.1 Vaccine Contract Manufacturing Competition
8.3.2 Target Diseases For Vaccine Development
8.3.3 Challenge Stock Vaccines
8.3.4 Meridian’s Vaccine Contract Manufacturing Revenue Stream Breakdown
8.3.5 The Changing Face of Large Pharma Drives Contract Manufacturing Growth
8.4 Interview with Dr Stefan Beyer, Managing Director, Vibalogics
8.4.1 The Benefits of Outsourcing Vaccine Manufacturing
8.4.2 The Challenges in Manufacturing Vaccines
9. Conclusion
9.1 Overview
9.2 Regulatory and Quality Standards Create High Barriers of Entry
9.3 Rich Pipeline for Therapeutic Vaccines
9.4 Emerging Markets will Show Stronger Growth
9.5 Technology Drives Changes in Manufacturing
【レポート販売概要】
■ タイトル：世界のワクチン製造技術およびサービス市場（2014-2024）■ 英文：Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024
Prospects For Leading Players
■ 発行日：2014年3月
■ 調査会社：visiongain
■ 商品コード：Visiongain-4052640
■ 調査対象地域：グローバル
- 世界における自動車軽量化の材料技術市場：アルミニウム、炭素繊維、プラスチック及び複合材、マグネシウム、鋼鉄This latest just-auto report edition offers a global review of the vehicle lightweighting megatrend, its suppliers, top markets, technologies and market forecasts. This global market study offers: A comprehensive overview of lightweight developments for each of the following areas: Body and exterior – body-in-white; doors; front-end modules; glazing Chassis – suspension and braking components Inte …
- 世界の神経調節市場：脊髄刺激、迷走神経刺激などNeuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non–invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart fa …
- 過酸化水素(HP)の世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world hydrogen peroxide market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true …
- グローバル・エグゼクティブ・サーベイ：プライベート・ラベル市場における顧客の期待と企業の戦略的アプローチSummary “Private Label - Consumer Expectations and Organizations Strategic Approach” is a report published by Canadean with a detailed analysis about the quality of private label goods, organizations plans on adoption and strengthening of private label, also coverage of their apprehensions about private label brands and retailers. Key Findings - Overall, 61% of executives indicate that private lab …
- ICT調達動向：中規模企業部門 – 企業のICT投資計画Why was the report written? To highlight the criteria on which medium-sized enterprises select their ICT providers as well as the roles which have influence while making ICT purchasing decisions. What is the current market landscape and what is changing? Medium-sized enterprises have an optimistic approach towards IT investments, and their preference towards hosted services is slowly gaining tract …
- アンドロイド端末データベース：ベンダー別、モデル別、地域別ユーザー数（Android Devices Database: Activations by Vendor, Handset Model & Region Q1'2012）While Android growth is slowing down, the Google backed operating system still maintained triple figure Year-on-Year (YoY) growth of + 126 % in Q1’2012. With nearly 85 million shipments in Q1’2012, Android Smartphones maintained market domination within the Smartphone segment of the market, with a global market share of 59 % and increasing the installed base of legitimate Android device (handset) …
- 世界のIGBT及びサイリスタ (Thyristor) 市場分析と予測（2013～2018）Electric power is the most essential component in human life, and life would come to a standstill without it. Thus, there is a need to enhance the transmission system. The IGBT & Thyristor market is in its growth stage and penetrating very fast. Since its invention in the early 1980s, the IGBT has become the dominant power of semiconductor in converters for mass transit applications. IGBT has beco …
- 脂漏性角化症治療剤の世界市場2019-2023About this market The surge in geriatric population will lead the seborrheic keratosis treatment market to witness considerable growth in the forthcoming years. Rapid developments in the healthcare facilities and advanced treatment options have further resulted in increasing the life expectancy of the geriatric population. Rising awareness about the health conditions including seborrheic keratosis …
- 因子検査市場：米国、ヨーロッパ、日本The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and Factor Assays testing specifically, will become more standardized, offeri …
- ヘビーデューティ型ポンプの世界市場ABSTRACTAbout Heavy Duty Pumps Heavy-duty pumps are mechanical devices that are used to transport fluids. These pumps have major applications in industries such as construction, mining, oil and gas, wastewater, pulp, pharmaceutical, and food and beverage. The major end-users of the market include oil and gas, processing, and other industries. The rise in investment in pumps by these end-user segme …
- 燃料添加剤の世界市場2015-2019Technavio's market research analyst estimates the global fuel additives market to witness a steady growth at a rate of around 8% during the forecast period. The adoption of ethanol and biodiesel is expected to drive the market growth for fuel additives due to the usage of antioxidants, corrosion inhibitors, cold flow improvers, and other products. The rise in the adoption of hybrid electric vehicl …
- 世界の多発性硬化症治療薬市場（2014-2018）About Multiple Sclerosis and Disease Types Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myeli …
- コンクリート混和剤の世界市場：高流動化剤、可塑剤、促進剤、空気連行剤、緩和剤、防水剤The concrete admixtures market size, in terms of value, is estimated to reach USD 18.10 Billion by 2020, signifying a firm CAGR of over 9.15% between 2015 and 2020. The drivers identified for the concrete admixtures market are growing infrastructure requirements in developing economies, improving economics of construction, and shifting preferences of population towards urbanization. High growth ma …
- アルミ複合パネルの世界市場分析：製品別（PVDF、ポリエステル、ラミネート被覆、酸化膜）、用途別（建設、自動車、広告板、鉄道）、地域別、セグメント予測 -2014-2025The global aluminum composite panels market is expected to reach USD 8.26 billion by 2025, according to a new report by Grand View Research, Inc. The rapid growth of the construction and infrastructure industries, most notably in emerging regions, is expected to drive the growth of the aluminum composite panels (ACP) market over the coming years. The growth in population and urbanization have resu …
- 世界におけるフォームドレッシングの製品パイプライン動向2015Foams - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Foams - Pipeline Review, 2015" provides an overview of Foams currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. I …
